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Lysophosphatidic acid (LPA) is a pleiotropic extracellular lipid mediator with many
physiological functions that signal through six known G protein-coupled receptors
(LPA1–6). In the central nervous system (CNS), LPA mediates a wide range of effects
including neural progenitor cell physiology, neuronal cell death, axonal retraction, and
inflammation. Since inflammation is a hallmark of most neurological conditions, we
hypothesized that LPA could be involved in the physiopathology of amyotrophic lateral
sclerosis (ALS). We found that LPA2 RNA was upregulated in post-mortem spinal cord
samples of ALS patients and in the sciatic nerve and skeletal muscle of SOD1G93A
mouse, the most widely used ALS mouse model. To assess the contribution of LPA2
to ALS, we generated a SOD1G93A mouse that was deficient in Lpar2. This animal
revealed that LPA2 signaling accelerates disease onset and neurological decline but,
unexpectedly, extended the lifespan. To gain insights into the early harmful actions of
LPA2 in ALS, we studied the effects of this receptor in the spinal cord, peripheral nerve,
and skeletal muscle of ALS mice. We found that LPA2 gene deletion increased microglial
activation but did not contribute to motoneuron death, astrogliosis, degeneration, and
demyelination of motor axons. However, we observed that Lpar2 deficiency protected
against muscle atrophy. Moreover, we also found the deletion of Lpar2 reduced the
invasion of macrophages into the skeletal muscle of SOD1G93A mice, linking LPA2
signaling with muscle inflammation and atrophy in ALS. Overall, these results suggest for
the first time that LPA2 contributes to ALS, and its genetic deletion results in protective
actions at the early stages of the disease but shortens survival thereafter.
Keywords: amyotrophic lateral sclerosis, LPA2, lysophosphatidic acid, lysophosphatidic acid receptor,
inflammation, motoneuron, muscle atrophy
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disease caused by the progressive degeneration of motoneurons
in the spinal cord and the brain. ALS leads to muscle weakness,
spasticity, paralysis, and eventually the death of the patients
within 2–5 years of clinical onset in the majority of the cases.
At present, therapy is mainly symptomatic and fails to halt
disease progression (Philips and Robberecht, 2011; Robberecht
and Philips, 2013; Hardiman et al., 2017) ALS is inherited in
5–10% of cases but approximately 90–95% of ALS patients have
no apparent family history and are often termed ‘‘sporadic ALS’’
(sALS; Philips and Robberecht, 2011; Robberecht and Philips,
2013). Nevertheless, they all share similar pathological features
and are clinically indistinguishable.
A common feature of ALS and other neurological disorders
is the occurrence of an inflammatory response in the central
nervous system (CNS), peripheral nervous system (PNS), and
muscles (Nagai et al., 2007; Yamanaka et al., 2008; Frakes
et al., 2014; De Virgilio et al., 2016; Newcombe et al., 2018;
Bright et al., 2019). Although immune cells play a crucial
role in protecting host tissues from infection and help at
maintaining homeostasis, immune cells also secrete various
cytotoxic mediators that promote damage in healthy neighboring
cells and cause cell death (López-Vales and David, 2012; Gilhus
and Deuschl, 2019) This double-edged sword of inflammation
likely depends on regulatory mediators that are present in the
extracellular milieu. In neurological conditions, including ALS,
an inflammatory response is believed to trigger more hazardous
than protective actions, and thus, attenuating inflammation
could reduce axonal damage and motor neuron degeneration
in ALS (Appel et al., 2010; Philips and Robberecht, 2011;
Robberecht and Philips, 2013).
Several studies have revealed the importance of
lysophosphatidic acid (LPA) in modulating inflammation,
including in the central nervous system (CNS; Choi et al.,
2010; Choi and Chun, 2013; Yung et al., 2014, 2015). LPA is
a lysophospholipid that is a potent lipid-signaling molecule
with many different actions in the CNS including neural
development (Hecht et al., 1996), axonal retraction (Bräuer
et al., 2003; Broggini et al., 2010), neuronal death (Kingsbury
et al., 2003; Steiner et al., 2006; Ramesh et al., 2018; Zhang
et al., 2020), and inflammation (Kwon et al., 2018; Plastira et al.,
2020). Moreover, LPA signaling has been related to various
neurological disorders including psychiatric diseases (Mirendil
et al., 2015; Yamada et al., 2015; Schneider et al., 2018; Tabbai
et al., 2019), Alzheimer’s disease (Hwang et al., 2012; Shi et al.,
2013; Ramesh et al., 2018) spinal cord injury (Goldshmit et al.,
2012; Santos-Nogueira et al., 2015; López-Serrano et al., 2019),
and the appearance of neuropathic pain responses (Lin et al.,
2012; Ueda et al., 2013, 2018; González-Gil et al., 2020).
LPA mediates all these effects by signaling through 6 G
protein-coupled receptors (LPA1–LPA6; Chun et al., 2013;
Kihara et al., 2014). These receptors are expressed in almost
all cells of the CNS and peripheral tissues (Choi et al., 2010;
Choi and Chun, 2013; Yung et al., 2014, 2015). We have
previously demonstrated that LPA1 and LPA2 contribute to the
physiopathology of spinal cord injury by modulating microglial
activation (Santos-Nogueira et al., 2015; López-Serrano et al.,
2019). However, whether LPA exerts harmful or beneficial
actions in ALS is currently unknown.
In the present work, we provide evidence for the first time that
LPA contributes to ALS pathology. In particular, we found that
the lack of LPA2 signaling reduces macrophage infiltration into
the muscle andmuscle atrophy in ALS animals, and slows disease
onset and neurological deficits. However, the lack of this receptor
paradoxically shortens the survival of SOD1G93A mice.
MATERIALS AND METHODS
Human Samples
Human samples obtained from ALS patients and controls were
gently provided by the Institute of Neuropathology HUB-ICO-
IDIBELL Biobank. The post-mortem interval between death and
tissue processing was between 2 and 17 h. Necropsy samples
of the spinal cord from human ALS patients (n = 22) and
age-matched controls (n = 17) were removed and kept at −80◦C
or fixed by immersion in 4% buffered formalin. The lumbar
anterior spinal cord was dissected frozen on a plate over dry
ice using a binocular microscope at a magnification ×4. Cases
with frontotemporal dementia were not included in the present
series. Patients with associated pathology including Parkinson’s
disease, Alzheimer’s disease (excepting neurofibrillary 103 tangle
pathology stages I–II of Braak and Braak), tauopathies, vascular
diseases, neoplastic diseases affecting the nervous system,
metabolic syndrome, hypoxia, and prolonged axonal states such
as those occurring in intensive care units were excluded. Cases
with infectious, inflammatory, and autoimmune diseases, either
systemic or limited to the nervous system were not included.
Age-matched control cases had not suffered from neurologic
or psychiatric diseases and did not have abnormalities in the
neuropathologic examination, excepting sporadic neurofibrillary
tangle pathology stages I–II of Braak and Braak. No C9ORF72,
SOD1, TARDBP, and FUS mutations occurred in any case.
Animals
SOD1G93A mice [B6-Tg (SOD1-G93A)1Gur] were purchased
from Jackson Laboratory (Bar Harbor, ME, USA). SOD1G93A
mice were heterozygous for the mutant SOD1 gene (Bright et al.,
2019). This experimental model replicates the most relevant
phenotypical and histopathological features of the human disease
(Turner and Talbot, 2008). Lpar2 deficient mice (mixed BL6/SVJ
background) were provided by Dr. Jerold Chun (Contos et al.,
2002). Lpar2 null mice and wild-type littermates were crossed
with SOD1G93A mice to generate double transgenic mice that
express mutant SOD1G93A in heterozygosis but are homozygous
knockout for Lpar2 (Lpar2−/−). A total of 215 mice were used
in this study. All mice used in the studies were housed in the
Universitat Autònoma de Barcelona animal facilities, in standard
cages and feed ad libitum with a light-dark cycle of 12 h.
Rotarod and Survival
Rotarod test was done to assess motor deficits and define the
disease onset in SOD1G93A mice (Miana-Mena et al., 2005). Mice
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were placed onto the rotarod at a constant speed of 14 revolutions
per minute. Animals were trained before the beginning of the
experiment. 180 s was chosen as the arbitrary cut-off time.
Rotarod test was then performed weekly from 8 to 20 or 22 weeks
of age at the same speed. The time for which each animal could
remain on the rotating cylinder was measured. Each animal
was given three trials and the longest latency without falling
was recorded.
The time of disease onset was defined at the time when
mice could not remain in the rotarod for at least 180 s. The
endpoint was determined when mice were not able to right
themselves within 30 s of being placed on their side. At the
endpoint, mice were euthanized by an overdose of pentobarbital
sodium (Dolethal, Vetoquinol) following the requirements of the
Animal Experimentation Ethical Committee of the Universitat
Autònoma de Barcelona.
Electrophysiological Test
Compound Muscle Action Potential (CMAP)
Animals were anesthetized with pentobarbital sodium (50mg/kg,
i.p, Sigma) and placed prone over a heating pad that maintains
body temperature. Needle electrodes were placed deep into
the sciatic nerve notch and the sciatic nerve was stimulated
using single pulses of 0.02 ms duration (Grass S88) Recording
microneedles were inserted superficially in the tibial anterior
muscle. The recording needles were placed using a magnifier lens
and guided by anatomical landmarks, to ensure reproducibility
of needle location on all animals. Reference and ground
electrodes were inserted at the third toe and the base of
the paw, respectively. CMAPs were recorded from the tibialis
anterior and gastrocnemius muscle. Signals were bandpass
filtered (3 Hz to 3 kHz), amplified 100× for gastrocnemius
and tibialis (P511AC amplifiers, Grass), and digitized with a
Power Lab recording system (PowerLab16SP, ADInstruments)
at 20 kHz. The amplitude of the M wave was studied
from the difference between the baseline to the maximal
negative peak.
Motor Unit Number Estimation (MUNEs)
Animals were anesthetized as described above. Electrodes were
placed in the same place as for the CMAP registers and the
amplitude for the M wave was recorded. For the MUNE
assessment, the protocol used consists of the incremental
technique. Starting from the subthreshold intensity, the sciatic
nerves were stimulated with single pulses of gradually increased
intensity until the first response appeared, representing the first
motor unit recruited. With the next stimuli, quantal increases
in the response were recorded. The data were represented
as the frequency distribution of the single motor unit size
(SU); as the mean of consistent increases (increments >100
µV) single motor unit potential (SMUP) and finally, MUNE
results from the CMAP maximal amplitude divided by the
average SMUP.
Sciatic Nerve Injury
Lpar2−/− mice and wild-type littermates were deeply
anesthetized with a mixture of ketamine (90 mg/kg i.m.;
Imagen, Merial) and xylazine (10 mg/kg i.m.; Rompun,
Bayer). The right hindlimb was shaved and disinfected,
and then, an incision in the skin and muscles was done to
expose the sciatic nerve. The sciatic nerve was cut above the
trifurcation and ligated to prevent axon regeneration and muscle
reinnervation. The wound was closed and disinfected, and the
mice were kept in a warm environment until complete recovery
from anesthesia. Buprenorphine (0.01 mg/kg i.p.; Buprex,
Indivior) was administrated intraperitoneally, twice a day, for
3 days.
Quantitative Real-Time PCR (qPCR)
SOD1G93A mice were transcardially perfused with sterile saline
at 8 (pre-symptomatic), 12 (disease onset), 16 (symptomatic),
and 20 weeks of age (late-symptomatic), and lumbar spinal
cord, sciatic nerve, and gastrocnemius muscle were harvested
and immediately frozen in liquid nitrogen. The same tissues
were also harvested from WT littermates at 20 weeks of age.
Samples were homogenized in QIAzol lysis reagent (Qiagen)
using a tissue rupture, and RNA was isolated using RNeasy
Lipid Tissue kit (Qiagen), according to the manufacturer′s
protocol. One microgram of RNA was retro-transcribed using
the Omniscript RT kit (Qiagen). Quantitative PCRs (qPCRs)
were done using Brilliant III Ultra-Fast SYBR (Bio-Rad) and
custom-designed primers. Primer sequences were the following
Lpar2 forward 5′-CTCACTGGTCAATGCAGTGGTATAT-3′,
Lpar2 reverse 5′-GAAGGCGGCGGAAGGT-3′. Glyceraldehyde
3-phosphate dehydrogenase (GAPDH); Gapdh forward 5′-
TCAACAGCAACTCCCACTCTTCCA-3′, Gapdh reverse 5′-
ACCCTGTTGCTGTAGCCGTATTCA-3′.
RNA from human spinal cord samples was isolated using
RNeasy Mini Kit (Qiagen) and retro-transcribed using cDNA
Reverse Transcription kit (Applied Biosystems, Foster City, CA,
USA) following manufacturers’ kit instructions. qPCR was done
using TaqMan-designed primers (Thermo Fisher Scientific, MA,
USA) for gene expression of LPA1 (Hs00173500_m1), LPA2
(Hs01109356_m1), and HPRT1 (Hs02800695_m1).
Mouse and human qPCR data were analyzed using the
double-delta cycle threshold (∆∆Ct) method on a MyiQ Single-
Color Real-Time PCR Detection System (Bio-Rad). Gapdh and
HRPT1 were used as housekeeping genes for mouse and human
samples, respectively.
Histology
SOD1G93A Lpar2+/+, SOD1G93A-Lpar2−/−, Lpar2 null mice and
wild-type littermates were euthanized at 16 weeks of age with
an overdose of pentobarbital sodium (Dolethal, Vetoquinol)
and transcardially perfused with 4% paraformaldehyde in 0.1 M
phosphate buffer (PB). Also, Lpar2 deficient mice and wildtype
littermates with sciatic nerve injury were perfused at 3 weeks
after the lesion. Samples were post-fixed in 4% PFA for 2 h
and cryoprotected with 30% sucrose in 0.1 M PB at 4◦C for
48 h. The spinal cords and muscles were fast-frozen at -20◦C
in a cryo embedding compound (Tissue-Tek OCT, Sakura),
cut on a cryostat (Leica), and serially picked up in gelatine
coated slides. The ventral root of the spinal nerve (L4) that
fixed into 3% glutaraldehyde, 3% PFA in 0.1 PB at 4◦C for
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1 week, immersed in 2% osmium tetroxide in 0.1 M PB
for 2 h, dehydrated through ethanol series and embedded in
Epon resin. Semithin sections (0.5 µm thick) were cut by an
ultramicrotome (Leica).
To analyze the preservation of motoneurons, transversal
sections of the spinal cord (L4 and L5) were placed in
a hotplate for 30 min, rehydrated, and stained in cresyl
violet. The number of motoneurons was manually quantified
in both ventral horns. To ensure reproducibility, only those
neurons that were within the laminae IX, were larger than
20 µm and had a polygonal shape and prominent nucleoli
were counted.
For immunofluorescence, spinal cord and muscle samples
were placed on a hotplate at 37◦C for 30 min, then rehydrated
in 0.1 PBS for 5 min and blocked with a blocking buffer
of 5% normal donkey serum (NDS) in 0.3% triton-PBS
for 1 h at RT. The sections were incubated overnight at
4◦C with primary antibodies against Iba1 (for microglia and
macrophages; 1:500; Abcam), CD68 (1:100; Abcam), GFAP
(for astrocytes; 1:500; Millipore). The sections were then
washed in 0.3% triton-PBS and further incubated for 1 h
at RT with the specific secondary antibodies tagged to an
Alexa-594 or Alexa-488 fluorochrome (1:200, Invitrogen). After
washing several times in 0.3% Triton-PBS and PBS, slides
were incubated for 1 min in a solution containing DAPI
(1 µg/ml, Sigma).
Microgliosis and astrogliosis were analyzed by quantifying
the integrated density of Iba, CD68, and GFAP immunostaining
at the spinal cord ventral horns of L4–L5 segments.
Macrophage counts in the gastrocnemius were done
by manually quantifying the number Iba1 and CD68
positive cells.
To analyze the muscle fiber area, cryostat transversal sections
of gastrocnemius muscle were hydrated in water and stained
for hematoxylin (Fluka, Sigma) and eosin (Merck, Millipore)
for 5 min. The sections were dehydrated with series of graded
ethanol rinses and mounted with DPX (Fluka).
To study motor axon preservation, ventral root (L4) semithin
sections, were stained with 1% Borax (Sigma) and 1% Toluidine
Blue (Fluka) in distillate water. The number of spared motor
axons, with intact myelin sheaths and those with some degree of
myelin damage were counted.
Samples were visualized with an Olympus BX51 microscope
and the images were captured with Olympus DP50 digital
camera. All Histological quantifications were done using ImageJ
software (NIH, Bethesda, MD, USA).
Statistical Analysis
Data are shown as mean ± standard error of the mean (SEM).
Rotarod test results were analyzed using two-way repeated-
measures ANOVA with post-hoc Bonferroni’s for multiple
comparisons. Disease onset and the survival data were analyzed
using the Mantel–Cox test. Gene expression, histological
analysis, and electrophysiological results were analyzed by
using one-way ANOVA with post-hoc Bonferroni’s for multiple
comparisons of unpaired t-test. Statistical significance was
considered at p < 0.05.
RESULTS
LPA2 Transcripts Are Increased in Human
and Mouse ALS Samples
LPA exerts its biological effects by binding to 6 G protein-
coupled receptors, known as LPA1–6. We have recently
demonstrated that among the different LPA receptors, LPA1
(Santos-Nogueira et al., 2015) and LPA2 (López-Serrano et al.,
2019) mediate demyelination and functional impairments in
spinal cord injury. Therefore, we first examined the RNA levels
of LPA1 and LPA2 in postmortem spinal cord samples of sALS
patients and age-matched controls. LPA1 and LPA2 transcripts
were found in the spinal cord of control and sALS individuals
(Figures 1A,B). However, only the levels of LPA2 significantly
increased in sALS samples (Figures 1A,B).
Based on these data, we focused our interest on LPA2 and
characterized its expression in the spinal cord, sciatic nerve, and
muscle of SOD1G93A mice. QPCR revealed that the expression
of Lpar2 in these three tissues was similar in SOD1G93A mice
at pre-symptomatic stages of the disease (8 weeks of age) than
in wild-type littermates (Figures 2A–C). RNA levels of Lpar2 in
the spinal cord of SOD1G93A mice tended to increase once they
show marked clinical symptoms of the disease (16–20 weeks of
age), although this result did not reach statistical significance
(Figure 2A). The transcripts of Lpar2 in the sciatic nerve and
gastrocnemius muscle of SOD1G93A mice increased significantly
over disease progression, peaking at the age of 16 weeks
(Figures 2B,C). At this time point, the RNA levels of lpar2 in
both tissues were ∼2.5 fold higher in SOD1G93A mice relative to
wildtype littermates (Figures 2B,C).
Genetic Deletion of Lpar2 Modifies ALS
Disease Course
To determine the contribution of LPA2 in ALS, we crossed
SOD1G93A mice with Lpar2 deficient mice (SOD1G93A-
Lpar2−/−). We observed that the absence of Lpar2 significantly
delayed ALS disease onset by 4 and 5 weeks in female and male
mice, respectively (Figures 3A–F). In this line, the rotarod
test also revealed that the genetic deletion of Lpar2 markedly
slowed the neurological decline of ALS mice (Figures 3A,D).
Unexpectedly, the lack of Lpar2 did not increase the lifespan of
SOD1G93A, despite its absence markedly protected against the
clinical signs of the disease (Figures 3G–J). Indeed, deficiency
of Lpar2 shortened the lifespan of ALS mice by 21 and 10 days,
in males and females, respectively (Figures 3H,J). Therefore,
these observations suggest that the lack of LPA2 signaling slows
disease onset and progression but shortens survival.
LPA2 Does Not Contribute to Motoneuron
Death in ALS
To gain insights into the early detrimental actions of LPA2
in ALS, we focused our experiments on SOD1G93A mice at
16 weeks of age, when neurological outcomes were markedly
enhanced in ALS mice lacking lpar2. Since LPA mediates gliosis
and we recently reported that microglial cells become cytotoxic
upon LPA2 stimulation (López-Serrano et al., 2019), we first
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FIGURE 1 | Characterization of Lysophosphatidic acid 1 (LPA1) and LPA2 expression in the spinal cord of sporadic amyotrophic lateral sclerosis (sALS) patients.
(A,B) Plots showing RNA levels of LPA1 (A) and LPA2 (B) in the spinal cord of sALS patients (n = 22) and controls (n = 17). Unpaired t-test. Data are shown as
mean ± SEM. ***p < 0.001.
FIGURE 2 | Dynamic changes in Lpa2 expression in SOD1G93A mice. (A–C) Graphs showing the changes in Lpar2 RNA levels in the spinal cord (A), sciatic nerve
(B), and gastrocnemius muscle (C) of SOD1G93A at 8, 12, 16, and 20 weeks of age relative to wild-type littermate mice. (A) n = 5 per group and time point. One-way
ANOVA with Bonferroni’s post hoc test. *p < 0.05, **p < 0.01 vs. WT mice. Data are shown as mean ± SEM.
evaluated whether LPA2 signaling contributed to microgliosis
and astrogliosis in the lumbar spinal cord of SOD1G93A
mice. Histological analysis revealed that immunoreactivity for
Iba1, a marker for microglial cells, tended to be increased
in the spinal cord ventral horn of ALS mice deficient in
Lpar2, although this result did not reach statistical significance
(Figures 4A,B). However, CD68 expression in microglial cells,
which is considered a marker of activated cells, was significantly
increased in ALS mice deficient in Lpar2 (Figures 4C,D),
suggesting that although the lack of Lpar2 signaling did not
increase microgliosis it resulted in greater activation of this glial
cell subset. Immunoreactivity for GFAP, a marker for astrocytes,
did not differ in the spinal cord of both ALS experimental groups
(Figures 4E,F).
Since degeneration of motoneurons is the main feature in
ALS mice and patients, we assessed whether LPA2 contributed
to motoneuron death. Histopathological analysis of the lumbar
spinal cord (L4 and L5) revealed that the lack of Lpar2 did
not have any effect on motoneuron survival in ALS mice
(Figures 5A,B) despite electrophysiological tests revealing that
the amplitude of the CMAPs was significantly increased in ALS
mice deficient in Lpar2 at 16 weeks of age (Figures 5C–F). These
results indicated that neuromuscular integrity was enhanced
in SOD1G93A mice lacking Lpar2 but this was not due to
detrimental actions of LPA2 onmotoneuron. These observations,
therefore, suggest that the initial harmful effects of LPA2
in ALS may be mediated in the peripheral nerve and/or
skeletal muscle.
LPA2 Does Not Promote Myelin Damage in
Motor Axons
LPA contributes to demyelination in the spinal cord by signaling
via LPA1 (Santos-Nogueira et al., 2015) and LPA2 (López-
Serrano et al., 2019). Considering that Lpar2 transcripts peaked
in the sciatic nerve of ALS mice at 16 weeks of age, we assessed
whether LPA2 led to demyelination and/or degeneration of
motor axons. For this purpose, we quantified the number of
fibers that showed some signs of Wallerian degeneration. These
analyses revealed that the counts of motor fibers that showed
signs of myelin breakdown did not differ between both ALS
groups (Figures 6A,B). These results, therefore, reveal that LPA2
does not promote demyelination in ALS.
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FIGURE 3 | Dual effects of LPA2 in ALS disease. (A–E) Graphs showing the functional evaluation of ALS mice in the rotarod test over time. (A,B) Lpar2 deficiency
delays the onset of the disease in 5 weeks in male ALS mice (A,B) and 4 weeks in females (D,E). Graphs showing the functional progression of neurological deficits
represented by the latency to fall off the rotarod test in males (C) and females (F). (G–J) Effects of Lpar2 gene deletion in the lifespan of ALS mice. Two-way RM
ANOVA, Bonferroni’s post hoc test in (A,B). Mantel-Cox test in (B,E,G,I). Unpaired t-test in (C,F,H,J). (A–C) Males (n = 9 SOD1G93A Lpar2+/+, n = 11 SOD1G93A
Lpar2−/−, n = 4 WT Lpar2+/+, n = 4 WT Lpar2−/−). (D–E) Females (n = 10 SOD1G93A Lpar2+/+, n = 11 SOD1G93A Lpar2−/−, n = 4 WT Lpar2+/+, n = 4 WT Lpar2−/−).
(G–H) Males (n = 14 SOD1G93A Lpar2+/+, n = 15 SOD1G93A Lpar2−/−). (I–J) Females (n = 14 SOD1G93A Lpar2+/+, n = 14 SOD1G93A Lpar2−/−). **p < 0.01,
***p < 0.001, vs. SOD1G93A LPA2+/+. Data are shown as mean ± SEM.
The Absence of Lpar2 Prevents Muscle
Atrophy in SOD1G93A Mice
Since the data reported above suggested that initial detrimental
actions of LPA2 in SOD1G93A mice were unlikely to be mediated
in the spinal cord or peripheral nerves, we then studied the effects
of Lpar2 deficiency in the muscle of ALS animals. Highlight
that lpar2 transcripts in the gastrocnemius muscle of SOD1G93A
mice peaked at the age of 16 weeks (Figure 2C). We found
that cross tissue sections of the gastrocnemius muscle stained
with hematoxylin and eosin revealed that the mean muscle fiber
area was decreased in SOD1G93A mice as compared to wildtype
mice, indicating clear signs of muscle atrophy (Figures 7A,B).
The mean muscle fiber area was slightly enhanced in ALS
mice lacking Lpar2, although this result did not reach statistical
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FIGURE 4 | The lack of Lpar2 does not reduce astrogliosis and microgliosis
in the lumbar spinal cord of SOD1G93A mice. (A) Representative images of the
lumbar spinal cord stained against Iba1. (B) Plot showing the quantification of
the Iba1 immunoreactivity in the L4 and L5 spinal cord segments.
(C) Representative images of the lumbar spinal cord showing stained against
CD68. (D) Graph showing quantification of CD68 immunoreactivity in the
L4 and L5 segments. (E) Representative images of the lumbar spinal cord
showing stained against GFAP. (F) Graph showing quantification of GFAP
immunoreactivity in the L4 and L5 segments. One-way ANOVA, Bonferroni’s
post hoc test. *p < 0.05 vs. SOD1G93A LPA2+/+ (males; n = 3 SOD1G93A
Lpar2+/+, n = 4 SOD1G93A Lpar2−/−, n = 4 WT Lpar2+/+, n = 4 WT Lpar2−/−).
Data are shown as mean ± SEM.
significance (Figures 7A,B). However, further analysis revealed
that the distribution of the muscle fiber according to their size
was shifted towards the right in ALS mice deficient for Lpar2.
These data indicated that the proportion of fibers with larger
diameter was increased in ALS lacking lpar2, whereas SOD1G93A
Lpar2+/+ animals displayed a greater proportion of small muscle
fibers (Figure 7C). These data, therefore, indicate that LPA2
signaling contributes to muscle atrophy in ALS.
To determine whether protection against muscle atrophy
observed in ALS mice deficient in Lpar2 was due to increased
collateral sprouting of motor axons, we assessed the integrity
of the neuromuscular junctions (NMJ) in the gastrocnemius
muscle. Electrophysiological estimation of the motor unit
number (MUNE), the mean amplitude of single motor unit
potential (SMUA), and the distribution of motor unit action
potential (MUAP) amplitude revealed that enhanced collateral
sprouting was not the mechanism that prevented muscle atrophy
in ALS mice lacking Lpar2 (Figure 8).
Previous work revealed that muscle was a primary target of
mutant SOD1 protein (SOD1G93A) and that selective expression
of SOD1G93A in skeletal muscle cells induced atrophy and
functional impairments (Dobrowolny et al., 2008). Therefore,
the attenuation of muscle atrophy and neurological decline
observed in ALS mice lacking Lpar2 could be due to the
deleterious actions of this LPA receptor on innervated muscle
fibers. However, the possibility that LPA2 signaling could be
required for the atrophy of denervated muscle fibers cannot be
discarded. To dissect out whether LPA2 signaling is crucial for
the atrophy of denervated fibers, we transected the sciatic nerve
of Lpar2 knockout mice and wildtype littermates to promote
muscle denervation and ligated the injured nerve to prevent
axon regeneration and muscle reinnervation. Histological cross-
sections of gastrocnemius muscles harvested at 21 after
lesion revealed that the lack of Lpar2 signaling did not
alter muscle atrophy caused by the denervation of the nerve
(Figures 9A–C). These data, therefore, indicated that LPA2
is not required for the atrophy of denervated fiber, and
suggested, that the reduced atrophy observed in ALS mice
lacking Lpar2 was due to greater protection of innervated
muscle fibers.
Recent studies reveal that immune cells infiltrate into the
muscles of SOD1G93A animals and that they contribute to
disease progression (Van Dyke et al., 2016; Trias et al., 2017).
Since LPA is involved in triggering inflammation (Choi and
Chun, 2013; Yung et al., 2014) we assessed whether LPA2
signaling is involved in regulating muscle inflammation in
ALS. Histological analysis of gastrocnemius muscle showed
that the number of macrophages (Iba1+ cells) was significantly
reduced in SOD1G93A mice lacking Lpar2 (Figures 10A,B).
In this line, the expression of CD68, which is found in
activated macrophages, was also reduced in the muscles of
ALS mice deficient in Lpar2 (Figures 10C,D), suggesting
that LPA2 signaling contributes to muscle inflammation
in ALS.
Discussion
In the present study, we assessed the effects of LPA2 on
ALS. We showed that LPA2 mRNA levels are increased
in post-mortem spinal cord samples of ALS patients, as
well as in the sciatic nerve and gastrocnemius muscle of
ALS mice. We also identified a biphasic role of LPA2 in
ALS. Initially, LPA2 signaling accelerates disease onset and
neurological deficits, whereas later, LPA2 extends survival. In
the search for the mechanisms underlying the harmful actions
of LPA2 at the early stages of ALS disease, we revealed this
receptor did not promote spinal cord gliosis, motoneuron
death, motor axon demyelination, but it increased muscle
atrophy and inflammation. Overall, this work provides, for
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FIGURE 5 | The lack of Lpar2 does not increase motoneuron survival but preserves neuromuscular integrity in ALS mice at 16 weeks of age. (A) Representative
micrograph of lumbar spinal cord showing motoneurons stained with cresyl violet. (B) Quantification of motoneurons in the L4 and L5 spinal cord segments (males;
n = 6 SOD1G93A Lpar2+/+, n = 9 SOD1G93A Lpar2−/−, n = 7 WT Lpar2+/+, n = 8 WT Lpar2−/−). (C,D) Plots showing the compound muscle potential amplitude of the
gastrocnemius (C,E) and tibialis anterior (D,F) muscle at 16 weeks of age (males; n = 14 SOD1G93A Lpar2+/+, n = 14 SOD1G93A Lpar2−/−, n = 5 WT Lpar2+/+,
n = 5 WT Lpar2−/−). **p < 0.01 vs. SOD1G93A LPA2+/+. One-way ANOVA, Bonferroni’s post hoc test. Data are shown as mean ± SEM.
the first time, evidence for the involvement of LPA2 in
ALS physiopathology.
Inflammation is a hallmark of neurodegenerative diseases,
typified by reactive morphology of astrocytes and microglia,
accompanied by the release of inflammatory mediators in the
parenchyma (Ransohoff, 2016). This physiological response
has been shown in ALS in both patients and animal
models (Philips and Robberecht, 2011), as well as, in most
neurological conditions including Alzheimer’s, Parkinson and
frontotemporal lobe dementia among others (De Virgilio et al.,
2016; Newcombe et al., 2018). Although most of the ALS
reports have focused on studying the inflammatory response
in the CNS, it is currently known that in ALS there is also
an invasion of immune cells into the peripheral nerves and
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FIGURE 6 | Lpar2 deletion does alter Wallerian degeneration of motor axons in SOD1G93A mice. (A) Representative cross-section images of the spinal nerve ventral
root (L4) stained in toluidine blue. Note the presence of fiber with disrupted myelin sheaths the motor roots of ALS mice (arrowhead). (B) Graph showing the
quantification of fibers with some signs of myelin degeneration at 16 weeks of age in male mice (n = 3 SOD1G93A Lpar2−/−, n = 5 SOD1G93A Lpar2+/+, n = 4 WT
LPA2−/−, n = 3 WT Lpar2+/+). Two-way ANOVA, Bonferroni’s post hoc test. Data are presented as mean ± SEM.
FIGURE 7 | Lpar2 gene deletion prevents muscle atrophy in SOD1G93A mice. (A) Representative images of gastrocnemius muscle stained in hematoxylin and eosin
at 16 weeks of age in male mice. (B) Quantification of the muscle cross-section area at 16 weeks of age in male mice. (C) Plot showing the distribution of muscle
fiber width (males; n = 4 per group). One-way ANOVA, Bonferroni’s post hoc test. #p < 0.05 vs. WT Lpar2+/+; ns, not significant vs. WT Lpar2-/- in (B); Two-way
ANOVA, Bonferroni’s post hoc test in (C). **p < 0.01 vs. SOD1G93A Lpar2+/+. Data are presented as mean ± SEM.
muscles that contributes to disease progression (Martínez-
Muriana et al., 2016; Van Dyke et al., 2016; Trias et al., 2017;
Trias et al., 2018, 2020).
Studies done over the last years have demonstrated that
lipids play a crucial role in the regulation of the inflammatory
response. Among them, lipids, such as the lysophospholipids
(LPLs; Chun et al., 2014), have demonstrated inflammatory
effects that are both detrimental and beneficial, including
within the CNS (David et al., 2012). LPA is an LPL that
acts as an extracellular and intracellular signaling molecule
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FIGURE 8 | The absence of Lpar2 does not enhance collateral sprouting.
(A–C) Electrophysiological estimation of motor unit number (A), mean
amplitude of single motor unit potential (B), and single size of motor units (C)
of the gastrocnemius muscle at 16 weeks of age in male mice. Note that the
absence of Lpar2 does not modify any of these parameters (males;
n = 5 SOD1G93A Lpar2−/−, n = 8 SOD1G93A Lpar2+/+, n = 5 WT Lpar2−/−,
n = 3 WT Lpar2+/+). One-way ANOVA with Bonferroni’s post hoc test in (A,B);
Two-way RM ANOVA with Bonferroni’s post hoc test in (C). Data shown as
mean ± SEM.
and controls a wide range of physiological responses. The
effects of LPA are mediated by 6 G protein-coupled receptors,
LPA1–LPA6 (Choi and Chun, 2013; Kihara et al., 2014;
Yung et al., 2015). Earlier studies demonstrated that this
bioactive lipid has important actions in the CNS after injury
and disease. LPA activates astrocytes and microglia, causes
axonal retraction, induces brain blood barrier permeability
among others (Sorensen et al., 2003; Choi et al., 2010).
We previously reported that LPA1 and LPA2 that are
normally associated with myelination (Weiner et al., 1998,
2001; Weiner and Chun, 1999; Anliker et al., 2013) also
cause demyelination and functional impairments after
spinal cord injury, in part, by activating microglial cells
(Santos-Nogueira et al., 2015; López-Serrano et al., 2019).
In the present work, we found that LPA1 and LPA2
RNA transcripts were expressed in post-mortem human
spinal cord samples and that the transcripts of LPA2, but
not LPA1, were increased ∼2 fold in sALS patients. The
expression of Lpar2 in the spinal cord of SOD1G93A mice
tended to increase once the clinical signs of the disease were
evident, although this up-regulation did not reach statistical
significance. Since ALS mouse samples were not harvested
at the disease endpoint, unlike the spinal cords of sALS
patients, this may account for the lower Lpar2 transcript
FIGURE 9 | Lpar2 deficiency does not prevent muscle atrophy after sciatic
nerve injury. (A) Representative images of gastrocnemius muscle cross tissue
sections at 21 days after sciatic nerve transection. (B,C) Plot showing the
quantification of the muscle cross-section area (B) and the distribution of
muscle fiber width (C). Lpar2−/− mice (n = 4) Lpar2+/+ mice (n = 6). Unpaired
t-student in (B); Two-way RM ANOVA with Bonferroni’s post hoc test in (C).
Data shown as mean ± SEM.
levels observed in the ALS animal model. We also found
that Lpar2 RNA levels were up-regulated in the sciatic
nerve and the gastrocnemius muscle of ALS mice, both
peaking at 16 weeks of age. The source of LPA2 in ALS
was not studied due to the lack of specificity of current
antibodies. However, Lpar2 transcripts in the CNS have
been described in neurons, oligodendrocytes, microglia, and
infiltrating macrophages, whereas in the peripheral nervous
system and skeletal muscle have been shown in Schwann cells
and muscle fibers, respectively (Frohnert et al., 2003; Jean-
Baptiste et al., 2005; Zhang et al., 2014).
To assess whether LPA2 signaling contributes to ALS, we
crossed mice lacking Lpar2 with SOD1G93A mice. This double-
transgenic animal revealed for the first time that the absence
of Lpar2 delayed the onset of ALS disease in both males and
females, and slowed the deterioration of locomotor performance.
Despite the detrimental actions of LPA2 at the initial stages
of the disease, deficiency in Lpar2 shortened the lifespan of
SOD1G93A mice. These data suggest that LPA2 signaling has
a dual role in ALS, being detrimental at the early stages
of the disease and later, being protective. However, we do
not discard that LPA2 signaling could play an important
physiological role for neuronal function, and its genetic removal
could increase their vulnerability to stress conditions. Therefore,
the development of LPA2 agonist is critical to elucidate
whether activation of this receptor confers protection at late
stages of ALS disease. Highlight that lifespan of SOD1G93A
mice was about 2 weeks increased than that reported from
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FIGURE 10 | Gene deletion of Lpar2 reduces macrophage invasion in the muscle of ALS mice. (A) Representative images of gastrocnemius muscle cross tissue
sections stained against Iba1. (B) Plot showing the quantification of the Iba1+ cells. (C) Representative images of gastrocnemius muscle cross tissue sections
stained against CD68. (D) Plot showing the quantification of the CD68+ cells. n = 4 per group. One-way ANOVA with Bonferroni’s post hoc test. ∗p < 0.05,
∗∗p < 0.01 vs. SOD1G93A Lpar2+/+. Data are presented as mean ± SEM.
Jackson Laboratories. This could be due to the background
acquired by ALS mice after being bred with the LPA2 mice.
However, other factors related to the loss of SOD1G93A gene
copies or the housing conditions of the animal facility, cannot
be discarded.
To elucidate the early pathological role of LPA2 in ALS,
we assessed its effects at different levels in which motor
function is involved (spinal cord, peripheral nerve, and muscle).
We first focused on the effects of LPA2 in the spinal
cord of ALS animals, where lower motoneurons are located
(Contos et al., 2002; Mancuso et al., 2014; McCampbell
et al., 2018). Despite having previously reported that activation
of LPA2 exerts deleterious effects after spinal cord injury
(López-Serrano et al., 2019), we observed that the lack of
Lpar2 did not modify the number of motoneurons in ALS
mice, suggesting that the harmful effects of LPA2 in ALS
were independent on motoneuron death. We also found
that the lack of Lpar2 did not attenuate astrogliosis but
increase the activation of microglial cells in the lumbar
spinal cord of ALS mice, as revealed the CD68 expression.
Although microglia and astroglia activation at later stages
of the disease was not studied in the present work, the
increased microglia reactivity observed in ALS mice deficient
in Lpar2 might indicate that this receptor could put the brakes
on microglia activation in advanced stages of the disease,
which may account for the shorter survival of ALS mice
lacking Lpar2.
In ALS, axonopathy precedes and underlies skeletal muscle
weakness and progressive paralysis. Indeed, peripheral axons
degenerate before the death of cell bodies in the CNS,
according to evidence in ALS patients and murine models
(Fischer and Glass, 2007; Moloney et al., 2014; Trias et al.,
2020). Unlike peripheral nerve injury, axonal growth of
degenerated axons is limited in ALS, leading to chronic and
progressive axon degeneration, recruitment of immune cells,
and promotion of inflammation (Trias et al., 2020). In this
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line, treatment with a CSF1R antagonist attenuated the influx
of macrophages into the nerves of ALS mice, that together
with its effects on minimizing microgliosis, extended mice
survival (Martínez-Muriana et al., 2016). Little is known
about the specific functions of LPA2 in the sciatic nerve, but
similar to LPA1, this receptor is found in Schwann cells and
its expression appears shortly before maturation/myelination
(Weiner and Chun, 1999; Weiner et al., 2001; García-Díaz
et al., 2015). Indeed, activation of LPA2 in myelinating cells
seems to play a key role in myelin formation (Weiner
and Chun, 1999; Weiner et al., 2001; Anliker et al., 2013;
García-Díaz et al., 2015).
Previous works revealed that LPA2 activation contributes
to demyelination after spinal cord injury (Santos-Nogueira
et al., 2015; López-Serrano et al., 2019) suggesting that the
upregulation of Lpar2 in the peripheral nerves of ALS mice could
mediate demyelination and/or damage inmotor axons. However,
histological analysis of the spinal cord motor roots of ALS mice,
where motor axons are present, revealed that the absence of
Lpar2 did not prevent degeneration of the axons or their myelin
sheaths, and suggested that the detrimental actions of LPA2 in
ALS could be mediated in the skeletal muscle.
Skeletal muscle atrophy in ALS has been interpreted as a
consequence of degeneration of motor axons. Nevertheless, it
has been recently postulated that skeletal myocytes also have
an active role in muscle atrophy in ALS, independent from
motoneuron loss. This is clear from experiments using mice with
selective expression of SOD1G93A in muscle cells, which revealed
that skeletal muscle is a primary target of SOD1G93A-mediated
toxicity and causes progressive muscle atrophy (Dobrowolny
et al., 2008). In this view, numerous studies have attempted
to palliate muscle pathology to counterbalance the effects of
motoneuron degeneration (Derave et al., 2003; Gifondorwa et al.,
2007; Yoo and Ko, 2012; Halon et al., 2014; Loeffler et al., 2016).
Here, we observed that Lpar2 deficiency protected from muscle
atrophy in ALS animals.
Collateral axonal sprouting is a natural mechanism observed
in ALS disease and nerve injury, among other disorders, in
which surviving motoneurons reinnervate denervated end-plates
within the same muscle, enabling to compensate for the loss
of functional motor units and prevent muscle atrophy (Siu and
Gordon, 2003). However, we revealed using electrophysiological
techniques that deficiency in Lpar2 did not enhance collateral
axonal sprouting in ALS. We also found that LPA2 signaling was
not required for the events that lead to atrophy of denervated
muscle fibers, since muscle atrophy caused by sciatic nerve
injury was not altered in Lpar2 null mice. These observations
suggested that LPA2 signaling contributed to skeletal muscle
atrophy of ALS mice by promoting deterioration of innervated
muscle fibers.
A recent study revealed that administration of LPA after
muscle injury worsens atrophy (Davies et al., 2017). The
same work demonstrated that the detrimental effects of LPA
in muscle injury were likely due to the actions of LPA on
inflammation since this biolipid increased the expression of
pro-inflammatory cytokines in the muscle and increased the
invasion of immune cells (Davies et al., 2017). As reported
above, mutant SOD1 protein causes a direct toxic effect
in the skeletal muscle cell and leads to muscle atrophy
(Dobrowolny et al., 2008). It is now known that different
immune cell subsets infiltrate the skeletal muscle of ALS
animals, which is likely due to the damage of muscle
fibers, and contribute to disease pathogenesis (Van Dyke
et al., 2016; Trias et al., 2018). Interestingly, we observed
that the infiltration of macrophages in skeletal muscles of
SOD1G93A mice was markedly attenuated in the lack of
Lpar2. These findings suggest that muscle damage caused by
mutant SOD1 favors the recruitment of macrophages into
the muscle, in part, by LPA2-dependent mechanisms, and
causes further muscle deterioration, and consequently, motor
function decline.
To summarize, this work provides the first evidence that
LPA2 signaling contributes to ALS. Initial activation of LPA2
accelerates ALS progression by promotingmuscle atrophy, which
is likely due to the inflammatory actions of this receptor in the
muscle, whereas later, it promotes beneficial effects on survival.
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